Combining sulfonylureas and other oral agents

American Journal of Medicine

Volumn 108, Issue 6 SUPPL. 1, 2000, Pages 15-22

  Riddle, Matthew ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIARRHEA; DIET; DISEASE COURSE; EXERCISE; FLATULENCE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEFICIENCY; INSULIN RELEASE; INSULIN RESISTANCE; LIVER TOXICITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0034678764     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(00)00338-7     Document Type: Conference Paper

References (23)

1. 1. Riddle MC. Tactics for type II diabetes. Endocrinol Metab Clin North Am. 1997;26:659-677.
2. 2. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
3. 3. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1997; 20(suppl 1):S5-S13.
4. 4. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995;18:258-268.
5. 5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1999;22(suppl 1):S5-S19.
6. 6. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999; 22(suppl 1):S27-S31.
7. 7. Groop LC, DeFronzo RA. Sulfonylureas. In: DeFronzo RA, ed. Current Therapy of Diabetes Mellitus. St. Louis, MO: Mosby, 1998;96-101.
8. 8. Bell PM, Hadden DR. Metformin. Endocrinol Metab Clin North Am. 1997;26:523-537.
9. 9. DeFronzo RA, Goodman AM, and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
10. 10. United Kingdom Prospective Diabetes Study (UKPDS) Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care. 1998;21:87-92.
11. 11. Hermann LS, Schersten B, Bitzen P-O, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care. 1994;17:1100-1109.
12. 12. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1994;121: 928-935.
13. 13. Horton ES, Whitehouse F, Ghazzi MN, et al. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. Diabetes Care. 1998;21: 1462-1469.
14. 14. Mathisen A, Geerloff J, Houser V, for the Pioglitazone 026 Study Group. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes (abstract). Diabetes. 1999;48(suppl 1):A102. (Abstract 0441.)
15. 15. Schneider R, Egan J, Houser V, for the Pioglitazone 010 Study Group. Combination therapy with pioglitazone and sulfonylurea in patients with type 2 diabetes (abstract). Diabetes. 1999;48(suppl 1):A106. (Abstract 0458.)
16. 16. Grunberger G, Weston WM, Patwardhan R, Rappaport EB. Rosiglitazone once or twice daily improves glycemic control in patients with type 2 diabetes (abstract). Diabetes. 1999;48(suppl 1):A102. (Abstract 0439.)
17. 17. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999;22:119-124.
18. 18. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficiency and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338:867-872.
19. 19. Fonseca V, Biswas N, Salzman A. Once-daily rosiglitazone in combination with metformin effectively reduces hyperglycemia in patients with type 2 diabetes (abstract). Diabetes. 1999;48(suppl 1):A100. (Abstract 0431.)
20. 20. Rosenstock J, Brown A, Fischer J, et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998;21:2050-2055.
21. 21. Yale J-F, Valiquett TR, Foyt H. Troglitazone efficacy and safety in combination with sulfonylurea and metformin as triple therapy (abstract). Diabetes. 1999;48(suppl 1):A118. (Abstract 0510.)
22. 22. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997; 102:491-497.
23. 23. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.